Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet‐Induced Obese (DIO) Rats
Abstract
Dapagliflozin is a potent and selective sodium glucose cotransporter‐2 (SGLT2) inhibitor which promotes urinary glucose excretion and induces weight loss. Since metabolic compensation can offset a negative energy balance, we explored the potential for a compensatory physiological response to the weight loss induced by dapagliflozin. Dapagliflozin was administered (0.5–5 mpk; p.o.) to diet‐induced obese (DIO) rats with or without ad libitum access to food for 38 days. Along with inducing urinary glucose excretion, chronic administration of dapagliflozin dose‐dependently increased food and water intake relative to vehicle‐treated controls. Despite this, it reduced body weight by 4% (relative to controls) at the highest dose. The degree of weight loss was increased by an additional 9% if hyperphagia was prevented by restricting food intake to that of vehicle controls. Neither oxygen consumption (vO2) or the respiratory exchange ratio (RER) were altered by dapagliflozin treatment alone. Animals treated with dapagliflozin and pair‐fed to vehicle controls (5 mpk PF‐V) showed a reduction in RER and an elevation in nonfasting β‐hydroxybutyrate (BHBA) relative to ad libitum‐fed 5 mpk counterparts. Fasting BHBA was elevated in the 1 mpk, 5 mpk, and 5 mpk PF‐V groups. Serum glucose was reduced in the fasted, but not the unfasted state. Insulin was reduced in the non‐fasted state. These data suggest that in rodents, the persistent urinary glucose excretion induced by dapagliflozin was accompanied by compensatory hyperphagia, which attenuated the weight loss induced by SGLT2 inhibition. Therefore, it is possible that dapagliflozin‐induced weight loss could be enhanced with dietary intervention.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Combinational approaches of incretin (co)agonists with diet and exercise may be superior strategies for sustainable weight loss compared to sole drug treatment.
“Moreover, although providing undoubtedly impressive effects on body weight, combinational approaches of incretin (co)agonists with diet and exercise may be superior strategies for sustainable weight loss compared to sole drug treatment [144,145].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [144]
SGLT2I mediate beneficial cardiovascular (particularly in chronic heart failure) and renal effects in people with and without type 2 diabetes.
“Further, SGLT2I mediate beneficial cardiovascular (particularly in chronic heart failure) and renal effects in people with and without type 2 diabetes [146,147].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [147]
Cites
Obesity and the Environment: Where Do We Go from Here?
Hill, J. O., Wyatt, H. R., Reed, G. W., & Peters, J. C. (2003) · Science · doi:10.1126/science.1079857 · Cited by 2,180 · see citing works
Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.250 · Cited by 396 · see citing works
Exercise in a Pill: Feasibility of Energy Expenditure Targets
Himms-Hagen, J. (2004) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007043337076 · Cited by 39 · cited 4× · see citing works
“chronic effects of dapagliflozin (5 mpk) on urine volume and glucose excretion in dIo rats (Table 2) ANOVA revealed significant treatment effects on urine volume (F (2, 18) = 105.”
BackgroundMethodInfluential
Flagged first, then by citations
Cited by
Sorted by citations
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975 · see citing works
Handelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice · doi:10.4158/ep161292.ps · Cited by 358 · see citing works
Progress and challenges in anti-obesity pharmacotherapy
Bessesen, D. H., & Van Gaal, L. F. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30236-x · Cited by 347 · see citing works
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221 · see citing works
Lee, P. C., Ganguly, S., & Goh, S. ‐. (2018) · Obesity Reviews · doi:10.1111/obr.12755 · Cited by 189 · see citing works
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169 · see citing works
Xu, L., & Ota, T. (2017) · Adipocyte · doi:10.1080/21623945.2017.1413516 · Cited by 134 · see citing works
Naznin, F., Sakoda, H., Okada, T., Tsubouchi, H., Waise, T. M. Z., Arakawa, K., & Nakazato, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.028 · Cited by 114 · see citing works
Hollander, P., Bays, H. E., Rosenstock, J., Frustaci, M. E., Fung, A., Vercruysse, F., & Erondu, N. (2017) · Diabetes Care · doi:10.2337/dc16-2427 · Cited by 106 · see citing works
Chiba, Y., Yamada, T., Tsukita, S., Takahashi, K., Munakata, Y., Shirai, Y., Kodama, S., Asai, Y., Sugisawa, T., Uno, K., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0150756 · Cited by 71 · see citing works
Thomas, D. M., Martin, C. K., Lettieri, S., Bredlau, C., Kaiser, K., Church, T., Bouchard, C., & Heymsfield, S. B. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.51 · Cited by 70 · see citing works
Sawada, Y., Izumida, Y., Takeuchi, Y., Aita, Y., Wada, N., Li, E., Murayama, Y., Piao, X., Shikama, A., Masuda, Y., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.09.081 · Cited by 31 · see citing works
- Authors
- Devenny, J. J., Godonis, H. E., Harvey, S. J., Rooney, S., Cullen, M. J., & Pelleymounter, M. A.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Corresponding author
- Pelleymounter, Mary Ann
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2012-08
- Volume
- 20
- Issue
- 8
- Pages
- 1645-1652
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W1990411608
- Cited by
- 212
- References
- 3
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 20 · 2023: 12 · 2022: 17 · 2021: 21 · 2020: 19 · 2019: 15 · 2018: 15 · 2017: 17 · 2016: 20 · 2015: 14 · 2014: 15 · 2013: 8 · 2012: 1
- FWCI
- 9.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Obesity (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- dapagliflozin, SGLT2 inhibitors, weight loss, diet-induced obesity, urinary glucose excretion, dietary intake, metabolic compensation, beta-hydroxybutyrate, respiratory exchange ratio, insulin, pair feeding, dietary intervention
- MeSH terms
- Animals, Benzhydryl Compounds, Blood Glucose, Energy Intake, Diet, Dose-Response Relationship, Drug, Drinking, Glucosides, Hyperphagia, Insulin, Male, Obesity, Oxygen Consumption, Respiration, Weight Loss, Treatment Outcome, Rats, Sprague-Dawley, Anti-Obesity Agents, 3-Hydroxybutyric Acid, Caloric Restriction, Sodium-Glucose Transport Proteins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
